

## CAN-FITE BIOPHARMA LTD.


## CONSOLIDATED STATEMENTS OF FINANCIAL POSITION


	Note	Convenience translation Into U.S. dollars Note 2.c.1		
		Year ended December 31,		December 31,
		2012	2012	2011
		in thousands	NIS in thousands	
LIABILITIES AND EQUITY				
CURRENT LIABILITIES:				
Trade payables	9	756	2,821	1,930
Other accounts payable	10	1,228	4,586	2,686
Warrants (series 5)	15	-	-	138
Warrants exercisable into shares (series 6)	15	40	149	396
Warrants exercisable into shares (series 7)	15	207	773	-
Warrants exercisable into shares (series 8)	15	96	357	-
		<u>2,327</u>	<u>8,686</u>	<u>5,150</u>
NON-CURRENT LIABILITIES:				
Warrants exercisable into shares (series 7)	15	-	-	793
Employee benefit liabilities, net	12	18	68	190
		<u>18</u>	<u>68</u>	<u>983</u>
		<u>2,345</u>	<u>8,754</u>	<u>6,133</u>
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:				
Share capital	15	732	2,734	2,606
Share premium		62,618	233,754	229,299
Capital reserve from share-based payment transactions		4,093	15,279	14,670
Warrants exercisable into shares (series 9)		179	669	-
Treasury shares, at cost		(1,555)	(5,805)	(5,805)
Other comprehensive income		23	84	75
Accumulated deficit		(67,334)	(251,359)	(230,539)
		<u>(1,244)</u>	<u>(4,644)</u>	<u>10,306</u>
Non-controlling interests		535	1,999	2,221
<u>Total deficit</u>		<u>(709)</u>	<u>(2,645)</u>	<u>12,527</u>
		<u>1,636</u>	<u>6,109</u>	<u>18,660</u>


The accompanying notes are an integral part of the consolidated financial statements.

April 11, 2013

Date of approval of the  
financial statements

  
Mr. Avigdor Kaplan  
Chairman of the Board

  
Prof. Pnina Fishman  
Member of the Board  
and Chief Executive

  
Mr. Motti Farbstein  
Deputy CEO, Operation  
and Responsible on